Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaojian Lin

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Acta Neuropathologica Communications|April 18, 2024
Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumorsYijun Cheng, Yuting Dai, Hao Tang, et al.
Neuro-Oncology|July 11, 2024
Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axisShaojian Lin, Liangbo Wang, Changxi Han, et al.
Chinese Neurosurgical Journal|June 9, 2026
Chinese consensus on the diagnosis and treatment of prolactinomas (2025 edition)Shaojian Lin, Zhengyuan Chen, Lijin Ji, et al.
Neuro-Oncology|June 23, 2026
A MYCN-GAL-SREBP1 Lipogenic Axis Drives Proliferation in Silent Corticotroph AdenomasChangxi Han, Junchen Wu, Jing Xie, et al.
Endocrine|January 21, 2026
Endoscopic surgery for noninvasive prolactinomas: A large multicenter, single-arm, retrospective study (PRLomaSaR)Yijun Cheng, Yu Wang, Wenwen Lv, et al.
Neuro-Oncology|February 26, 2022
TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPITHong Yao, Wanqun Xie, Yuting Dai, et al.
Genome Medicine|April 24, 2024
Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumorsShaojian Lin, Yuting Dai, Changxi Han, et al.
Signal Transduction and Targeted Therapy|November 18, 2025
Multidimensional tumor-blood profiling uncovers systemic lymphocyte-monocyte imbalance in pituitary neuroendocrine tumorsYuting Dai, Shaojian Lin, Junchen Wu, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Acta Neuropathologica Communications|April 18, 2024
Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumorsYijun Cheng, Yuting Dai, Hao Tang, et al.
Neuro-Oncology|July 11, 2024
Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axisShaojian Lin, Liangbo Wang, Changxi Han, et al.
Chinese Neurosurgical Journal|June 9, 2026
Chinese consensus on the diagnosis and treatment of prolactinomas (2025 edition)Shaojian Lin, Zhengyuan Chen, Lijin Ji, et al.
Neuro-Oncology|June 23, 2026
A MYCN-GAL-SREBP1 Lipogenic Axis Drives Proliferation in Silent Corticotroph AdenomasChangxi Han, Junchen Wu, Jing Xie, et al.
Endocrine|January 21, 2026
Endoscopic surgery for noninvasive prolactinomas: A large multicenter, single-arm, retrospective study (PRLomaSaR)Yijun Cheng, Yu Wang, Wenwen Lv, et al.
Neuro-Oncology|February 26, 2022
TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPITHong Yao, Wanqun Xie, Yuting Dai, et al.
Genome Medicine|April 24, 2024
Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumorsShaojian Lin, Yuting Dai, Changxi Han, et al.
Signal Transduction and Targeted Therapy|November 18, 2025
Multidimensional tumor-blood profiling uncovers systemic lymphocyte-monocyte imbalance in pituitary neuroendocrine tumorsYuting Dai, Shaojian Lin, Junchen Wu, et al.
Pageof 7